Method for decreasing low density lipoprotein levels
OwnerCynthia L. Bristowinventor
Life of this patent
Estimating the term…
Abstract
The present invention features, in certain aspects, methods of promoting endocytosis of LDL with α1PI or peptides derived from α1PI. The present invention also provides methods for decreasing LDL levels in response to α1PI augmentation therapy. In preferred embodiments, the methods are suitable for a subject who is suffering from a disease or disorder selected from heart disease, atherosclerosis, hypertension, HIV infection, viral infection, bacterial infection, leukemia, a solid tumor, or autoimmune disease.
Claims22
A method of decreasing low density lipoprotein (LDL) levels in a subject comprising:
- identifying a subject in need of such treatment, administering to the subject a therapeutically effective amount of active alpha.1PI and monitoring the levels of LDL after said administration;
- thereby decreasing the levels of LDL in the subject.
A method of modulating the distribution of LDL levels, HDL levels, cholesterol levels, triglyceride levels and other lipids derived from LDL, HDL, cholesterol, and triglycerides in a subject comprising the steps of:
- identifying a subject in need of such treatment and administering to the subject a therapeutically effective amount of active .alpha.1P 1PI;
- thereby modulating the distribution of LDL levels, HDL levels, cholesterol levels, triglyceride levels and other lipids derived from LDL, HDL, cholesterol, and triglycerides in the subject.
3-6. (canceled)
A method of treating a subject with a disease associated with an increase in the level of LDL, comprising:
- identifying a subject in need of such treatment;
- administering to said subject a therapeutically effective amount of active .alpha.1PI;
- and determining the level of LDL in said subject after said administration;
- wherein, following said administration, there is a decrease in the level of LDL in said subject, thereby treating said disease.
16-17. (canceled)
A method of treating a subject diagnosed with a disease associated with an increase in the level of LDL comprising:
- administering to a subject in need of such treatment a therapeutically effective amount of active alpha 1PI;
- and monitoring the level of LDL of said subject before and after administration of said active alpha 1PI.
19-28. (canceled)
31-36. (canceled)
Dependencies are inferred from the claim text.